Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadershipPhase 1/2a trial now expe...
JP Morgan analyst Brian Cheng initiates coverage on Absci (NASDAQ:ABSI) with a Overweight rating.
Absci teams up with Oracle and AMD to enhance AI-driven drug discovery using high-performance GPUs.
Morgan Stanley analyst Vikram Purohit maintains Absci (NASDAQ:ABSI) with a Overweight and lowers the price target from $6.4 ...
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $9 to $8.
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14...
